Recent Advances of Researches on Expression, Function and Regulation of CD22.
10.7534/j.issn.1009-2137.2015.02.054
- Author:
Xiao-Jing WU
1
;
Zong-Hong SHAO
2
Author Information
1. Department of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China.
2. Department of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China. E-mail: shaozonghong@sina.com.
- Publication Type:Journal Article
- MeSH:
Autoimmune Diseases;
B-Lymphocytes;
Humans;
Phosphorylation;
Receptors, Antigen, B-Cell;
Sialic Acid Binding Ig-like Lectin 2;
Signal Transduction
- From:
Journal of Experimental Hematology
2015;23(2):573-577
- CountryChina
- Language:Chinese
-
Abstract:
CD22 is a type I transmembrane protein expressed on most mature B lymphocyte, and plays a significant role in signal transduction pathways. CD22 acts as a co-receptor of the B-cell receptor (BCR) that inhibits the BCR signaling by antigen-receptor interaction. The phosphorylation of CD22 can be triggered by cross-linking of CD22 with the BCR through antigen, then predominantly triggers the dephosphorylation and inactivation of downstream proteins and inhibit the BCR signaling. Autoimmune disease could be caused by the abnormal expression or dysfunction of CD22 which interrupts BCR signaling and then influences the quantity and function of B cells. The further study of the function and regulation of CD22 would help us understanding the pathogenesis of autoimmune disease and setting theoretical basis for its targeting treatment. In this article, the structure and expression of CD22, the ligands of CD22, the regulation of BCR and transmenbrane signaling, the effect of CD22 on B cells, and CD22 and autoimmune diseases were reviewed.
